graft-versus-tumor

graft-versus-tumor

Immunology An immune response to a graft recipient's tumor cells by a donor's transplanted immune cells in the BM or peripheral blood. See Graft-versus-host disease.
References in periodicals archive ?
Furthermore, in certain types of blood cancers, there is a graft-versus-tumor (GVT) effect that occurs wherein the white blood cells transplanted from the donor (graft) seek out the remaining tumor cells after chemotherapy, and attack them.
Malignant tumor-bearing mice treated with allo-HSCT + TT showed a strong graft-versus-tumor (GVT) effect but weak GVHD compared with HSCT alone and HSCT + DLI.
Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
We chose the graft-versus-tumor (GVT) approach with allogeneic hematopoietic stem cell transplantation (allo-HSCT) as a potentially curative treatment to avoid bilateral nephrectomy or local radiotherapy to both kidneys.
We performed an allogeneic HSCT because of the dismal prognosis and because delayed tumor regression after HSCT has been reported in a subset of adults with metastatic cancers, confirming the existence of a graft-versus-tumor effect in solid tumors [7].
In hematologic malignancies, the therapeutic efficacy of allo-SCT is due to the graft-versus-tumor (GVT) effect.
A phase I clinical trial of ipilimumab infusion in patients with relapsed malignancy following foreign (allogeneic) hematopoietic stem cell transplantation (Bashey 2009), when the majority of T cells of the patients derived from another person and therefore were attacking the patients' cells including their cancer cells, demonstrated that a CTLA-4 blockade by ipilimumab could augment the antitumor effect (graft-versus-tumor or GVT reaction) without a significant impact on the antihost effect (graft-versus-host disease or GVHD).
"If effective, this approach could prevent GVHD while sparing, at least in part, graft-versus-leukemia or graft-versus-tumor responses."
The disadvantage of autoHSCT compared with allogeneic HSCT is the absence of a graft-versus-tumor effect and the possibility that any malignant cells remaining in the graft could reengraft and lead to relapse of the patient's original disease.
"Patients with rapidly advancing metastatic disease, who would be unlikely to live long enough for the generation of a graft-versus-tumor effect, would not benefit from such therapy."
The study suggests the researchers turned the graft-versus-host reaction to some patients' advantage, making it a graft-versus-tumor response.
As a beneficial collateral effect on the host, a graft-versus-tumor can occur mediated by donor cell, lowering the risk of primary disease relapse.